| *Sponsored
Low Float (Nasdaq: TCRT) Has Multiple Technical Indicators Lit Up Going Into Monday
July 13th Dear Reader,
Obesity is a growing global health crisis, closely tied to rising rates of type 2 diabetes, cardiovascular disease, and other serious conditions.
Despite the expansion of the o.besity drug market—valued at $15Bn and is projected to reach $150Bn by 2030—current therapies, including lifestyle changes, older pharmaceuticals, and newer G.L.P-1 receptor agonists, face limitations related to efficacy, side effects, cost, and accessibility.
This report introduces a preclinical-stage company developing a differentiated small molecule-based therapy, aiming to address unmet needs and offer a novel solution for o.besity and related metabolic disorders.
But that's not all we're focusing on...
A low float? Yes. Triggered technical indicators? Yes. Chart Support Growing? Have a look for yourself below!
For Monday AM, we've got this under-the radar Nasdaq idea on radar:
*Alaunos Therapeutics, Inc. (TCRT)*
Alaunos is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat o-besity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products.
Alaunos Therapeutics, Inc.'s (TCRT) New Angle Of Attack
Alaunos Therapeutics, Inc. is pursuing the development of a small molecule-based drug designed to treat o-besity and related metabolic disorders. This approach aims to offer a differentiated profile compared to currently marketed and in-development oral and injectable products.
ALN1001 and related small molecule product candidates are notable for not relying on hormonal manipulation, which is a common mechanism in many existing o.besity treatments. The company’s goal is to develop an oral o.besity compound that addresses several shortcomings of injectable G.L.P-1 receptor agonists, such as the preservation of lean muscle mass.
Alaunos has engaged a contract development and manufacturing organization (CMDO) to produce active pharmaceutical ingredients for its small molecule candidates. In the fourth quarter of 2024, the company initiated in vitro testing of these candidates.
Research and Development Progress
The ongoing in vitro study is designed to assess the impact of ALN1001 and its derivatives on lipid deposition and gene expression. Specifically, the study evaluates whether genes related to thermogenic activity, lipid metabolism, and energy regulation are activated or deactivated by treatment. The objective is to determine if these compounds positively influence fat and energy metabolism.
Results from this study are expected in the early second quarter of 2025 and will inform the development strategy for ALN1001 and its derivatives targeting o-besity, metabolic disorders, and inflammation. Candidates demonstrating the greatest efficacy in increasing metabolic activity and reducing fat accumulation may advance to evaluation in rodent models of o.besity.
If the in vitro study is successful, the company plans to conduct a proof-of-concept diet-induced o-besity (DIO) mouse study by the third quarter of 2025 to validate the mechanism of action. Subsequent steps would include Investigational New Drug (IND) application-enabling studies. Execution of these plans depends on study outcomes and the company’s ability to secure additional capital or partnerships.
Grab Sources Here: TCRT Form 10-K. -----
(Nasdaq: TCRT) - 4 Explosive Potential Catalysts Are Clamoring For Attention
#1. Bullish technical indicators.
Bullish technical indicators offer several key advantages for analyzing market trends and chart movements.
These tools help identify trends by highlighting periods when chart movements consistently reach higher highs and higher lows, signaling underlying market strength.
Indicators such as moving averages and momentum oscillators provide clear visual signals that filter out market noise, making it easier to recognize constructive patterns and potential turning points.
This data-driven approach, while not entirely reducing guesswork and emotional bias, allows for more objective decision-making based on observable patterns and quantitative evidence.
Ultimately, bullish technical indicators serve as valuable guides for understanding market psychology and anticipating potential future developments.
Barchart is reporting a cluster of bullish technical indicators:
Here's their list (as of 8:00PM EST Friday):
Short Term Indicators
- 20 Day Moving Average
- 20 - 50 Day MA Crossover
- 20 - 100 Day MA Crossover
- 20 - 200 Day MA Crossover
Medium Term Indicators
- 50 Day Moving Average
- 50 - 100 Day MA Crossover
- 50 - 150 Day MA Crossover
- 50 - 200 Day MA Crossover
Long Term Indicators
- 100 Day Moving Average
- 150 Day Moving Average
- 200 Day Moving Average
- 100 - Day Day MA Crossover
Barchart’s “Trend Seeker” composite indicator has also been activated.
#2. A low float.
A low share float—meaning only a small portion of a company’s total shares are available to the public—offers several distinct advantages.
First, a limited supply of available shares can lead to greater volatility.
This heightened volatility can be appealing for those interested in observing rapid market dynamics or studying the effects of supply and demand in real time.
Finally, companies with a low float may receive increased attention from retail participants, leading to unique patterns in market activity and public interest.
All this said, it's important to note, volatility can be a two-way street, as it can lead to quick vertical chart movements, both up and down.
According to info from the Yahoo Finance website, TCRT has a fairly low float.
The website reports this profile to have roughly 1.56Mn shares in its float.
This means that volatility could be on the menu on a daily basis.
#3. Potential chart support.
Take a look at TCRT's 1-year chart: | 
No comments:
Post a Comment